Design Therapeutics (NASDAQ:DSGN – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02, Yahoo Finance reports.
Design Therapeutics Stock Performance
NASDAQ DSGN opened at $4.21 on Wednesday. The firm’s fifty day moving average is $3.99 and its two-hundred day moving average is $3.55. Design Therapeutics has a one year low of $1.94 and a one year high of $7.83. The firm has a market cap of $237.84 million, a PE ratio of -4.01 and a beta of 1.83.
Analyst Ratings Changes
A number of research firms recently commented on DSGN. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 target price on shares of Design Therapeutics in a research report on Tuesday. Piper Sandler upgraded Design Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $6.00 to $12.00 in a research report on Tuesday, May 7th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.60.
About Design Therapeutics
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Read More
- Five stocks we like better than Design Therapeutics
- How to Use the MarketBeat Dividend Calculator
- Tenet Healthcare Stock Sees Strong Gains from Acute Care Boom
- Retail Stocks Investing, Explained
- Medical Technology Stock Benefits from Rising Acute Care Demand
- 3 Stocks to Consider Buying in October
- 3 High-ROIC Stocks to Watch During a Market Sell-Off
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.